Scientists have unveiled a groundbreaking technique to “rejuvenate” human eggs, a move that could significantly increase the success rates of IVF for older women. By targeting the root cause of age-related infertility, researchers from Ovo Labs and the Max Planck Institute believe they have found a way to reverse chromosomal defects in eggs before fertilization.
The Problem: The “Glue” of Life Degrades
As women age, the quality of their eggs declines primarily due to chromosomal errors, known as aneuploidy. By the time a woman reaches her mid-30s, more than half of her eggs may contain an incorrect number of chromosomes, leading to:
-
Increased risk of miscarriage.
-
Lower IVF success rates.
-
Higher instances of genetic conditions like Down syndrome.
The issue lies in meiosis, the process of cell division. In older eggs, the protein “glue” that holds chromosome pairs together begins to break down, causing them to separate incorrectly during fertilization.
The Solution: Shugoshin 1
The research team identified a specific protein called Shugoshin 1 that protects these chromosomal bonds. In their study, they microinjected this protein into donated human eggs to restore it to “youthful” levels.
The results were remarkable:
-
General Improvement: The rate of eggs with chromosomal defects dropped from 53% to 29%.
-
Women Over 35: For this group, the defect rate decreased from 65% to 44%.
-
Success in Fewer Cycles: Rather than the current “numbers game” of undergoing multiple IVF cycles to find one healthy egg, this technique aims to help women conceive within a single cycle.
The “Younger” Situation
“What is really beautiful is that we identified a single protein that goes down with age, returned it to young levels, and it has a big effect,” said Melina Schuh, director at the Max Planck Institute. She describes the process as simply restoring the egg to its “younger situation.”
While this technique cannot create new eggs or extend fertility beyond menopause, it offers a lifeline to women in their late 30s and early 40s who still have egg reserves but struggle with quality.
What’s Next?
Ovo Labs is currently in discussions with regulators to move toward clinical trials. The next critical step is determining whether these rejuvenated eggs consistently result in healthy embryos with fewer genetic errors. If successful, this could be the most significant advancement in fertility treatment in over a decade.
